Oxford Centre for Evidence-based Medicine – Levels of Evidence (March 2009)

《Oxford Centre for Evidence-based Medicine – Levels of Evidence (March 2009)》由会员上传分享，免费在线阅读，更多相关内容在教育资源-天天文库。

1、OxfordCentreforEvidence-basedMedicine–LevelsofEvidence(March2009)Whatarewetodowhentheirresistibleforceoftheneedtoofferclinicaladvicemeetswiththeimmovableobjectofflawedevidence?Allwecandoisourbest:givetheadvice,butalerttheadviseestotheflawsintheevidenceonwhichitisbased.The

2、CEBM‘LevelsofEvidence1′documentsetsoutoneapproachtosystematisingthisprocessfordifferentquestiontypes.(Fordefinitionsoftermsusedseeourglossary)LevelTherapy/Prevention,Aetiology/HarmPrognosisDiagnosisDifferentialdiagnosis/symptomprevalencestudyEconomicanddecisionanalyses1aS

3、R(withhomogeneity*)ofRCTsSR(withhomogeneity*)ofinceptioncohortstudies;CDR” validatedindifferentpopulationsSR(withhomogeneity*)ofLevel1diagnosticstudies;CDR” with1bstudiesfromdifferentclinicalcentresSR(withhomogeneity*)ofprospectivecohortstudiesSR(withhomogeneity*)ofLevel1

4、economicstudies1bIndividualRCT(withnarrowConfidenceInterval”¡)Individualinceptioncohortstudywith>80%follow-up;CDR” validatedinasinglepopulationValidating**cohortstudywithgood” ” ” referencestandards;orCDR” testedwithinoneclinicalcentreProspectivecohortstudywithgoodfollow-

5、up****Analysisbasedonclinicallysensiblecostsoralternatives;systematicreview(s)oftheevidence;andincludingmulti-waysensitivityanalyses1cAllornone§Allornonecase-seriesAbsoluteSpPinsandSnNouts” “Allornonecase-seriesAbsolutebetter-valueorworse-valueanalyses” ” ” “2aSR(withhomo

6、geneity*)ofcohortstudiesSR(withhomogeneity*)ofeitherretrospectivecohortstudiesoruntreatedcontrolgroupsinRCTsSR(withhomogeneity*)ofLevel>2diagnosticstudiesSR(withhomogeneity*)of2bandbetterstudiesSR(withhomogeneity*)ofLevel>2economicstudies2bIndividualcohortstudy(includingl

7、owqualityRCT;e.g.,<80%follow-up)Retrospectivecohortstudyorfollow-upofuntreatedcontrolpatientsinanRCT;DerivationofCDR” orvalidatedonsplit-sample§§§onlyExploratory**cohortstudywithgood” ” ” referencestandards;CDR” afterderivation,orvalidatedonlyonsplit-sample§§§ordatabasesR

8、etrospectivecohortstudy,orpoorfollow-upAnalysisbasedonclinicallysensiblecostsoralternatives;limi